

Hailing Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9588583/publications.pdf>

Version: 2024-02-01

17
papers

2,940
citations

623734

14
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

5734
citing authors

#	ARTICLE	IF	CITATIONS
1	BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. <i>Cell Death and Disease</i> , 2021, 12, 12.	6.3	12
2	Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2. <i>Oncogene</i> , 2021, 40, 6273-6283.	5.9	18
3	Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 518, 82-93.	7.2	16
4	Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. <i>Cancer Letters</i> , 2020, 475, 53-64.	7.2	17
5	Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer. <i>Redox Biology</i> , 2019, 24, 101225.	9.0	23
6	MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. <i>EBioMedicine</i> , 2019, 43, 225-237.	6.1	48
7	Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K inhibition through the transcriptional regulation of ER. <i>Cancer Letters</i> , 2019, 440-441, 54-63.	7.2	25
8	Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF- κ B signaling. <i>Cell Death and Disease</i> , 2018, 9, 809.	6.3	26
9	PI3K-p110 mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7095-7100.	7.1	75
10	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. <i>Gynecologic Oncology</i> , 2016, 142, 548-556.	1.4	80
11	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 2692-2704.	6.4	92
12	Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13153-13166.	1.8	66
13	Chemopreventive effects of aspirin at a glance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 254-263.	7.4	26
14	A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition. <i>Cancer Research</i> , 2014, 74, 15-23.	0.9	57
15	Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies. , 2013, , .		0
16	SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis. <i>Science Signaling</i> , 2009, 2, ra35.	3.6	137
17	Targeting the phosphoinositide 3-kinase pathway in cancer. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 627-644.	46.4	2,218